
⚠ COVID-19 INFORMATION: Resources, Vaccine Information
This is a Phase 3, 2-arm, multicenter study with an open-label ivacaftor arm and an observational arm to evaluate the safety and efficacy of long-term ivacaftor treatment in subjects with cystic fibrosis (CF) who are less than 24 months of age at treatment initiation and have an approved Ivacaftor-Responsive mutation